Biperiden

Trade names

• AKINETON

Actions

• Atropine-like blocking effect on all peripheral structures which are parasympathetic-innervated.
• M1 muscarinic acetylcholine receptor antagonist in CNS.
• Functional inhibitor of acid sphingomyelinase

Route of Administration

Oral (IM and IV formulations also exist)

Bioavailability

28-38% after oral administration

Plasma protein binding

60%

Half-life

18 to 24 hours

Metabolism

Hepatic

Elimination

Renal

Important side-effects

Memory problems, confusion, delirium, psychosis.

Dry mouth, constipation, ileus, urinary retention.

Tachycardia.

Should not be given to patients with untreated closed angle glaucoma.

Recommended dose

Start with 1mg two times daily and titrate after effect and tolerance.

The usual effective dose will be 1-4 mg 3-4 times daily.

Renal impairment

Not enough data exist on the use of biperiden in patients with impaired renal function.

Hepatic impairment

Not enough data exist on the use of biperiden in patients with impaired hepatic function.